Affiliation:
1. Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Abstract
Although oncogenic driver mutations in
RAS
occur in 20% of cancers, heterogeneity in the biologic outputs of different RAS mutants has hampered efforts to develop effective treatments for
RAS
-mutated cancers. In this issue of
Science Signaling
, Huynh
et al
. show that even among KRAS
Q61
mutants, the specific amino acid that is substituted substantially affects mutant KRAS biologic activity and oncogenicity.
Publisher
American Association for the Advancement of Science (AAAS)
Subject
Cell Biology,Molecular Biology,Biochemistry
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献